(Date:11/24/2009)...SNewswire/--Newpeer-revieweddatafindingthatfewerth...hchronichepatitisCvirushavereceivedanti-viralthera...dstomoveurgentlyonbipartisanlegislationtosupportne...rts,the NationalViralHepatitisRoundtable(NVHR) sai...action,millionsofAmericansinfectedwithchronichepat...
(Date:11/23/2009),, NEWYORK,Nov.23/PRNewswire/--Livingwithchronicpaincanbedifficult-andthestressoftheholidayseasoncanprovetobequitechallengingforthoselivingwithpain. ,, ListentothisreportfromPfizerInc.at: ,
(Date:11/23/2009)...ing from women,s hair loss for almost ten years, Z...aring her progress and the secret behind her succe...se of her video diaries which include a direct com...t. , (PRWeb UK) November ... Siklosi has released the video diaries that docum...
(Date:11/23/2009)...FirstCall/--InfoLogix,Inc.(Nasdaq: IFLG ),aleading...thehealthcareandcommercialindustries,announcedtoda...SiemensHealthServices,hasjoinedInfoLogixasVicePres...ttp://www.newscom.com/cgi-bin/prnh/20090618/NE3513...ServicesforInfoLogix,Mr.Waywillberesponsibleforthe...
(Date:11/23/2009)...d survivors treated with chemotherapy suffer insom...onditions, hindering patients, ability to fully re...f Rochester Medical Center. , A study of 823 can...s at nearly three times the rate of the general po...r patients and those with lung and breast cancers,...
Breaking Medicine News(10 mins):Health News:NVHR: New Data Finding Fewer than 1 in 5 Hepatitis C Patients Receiving Antiviral Therapy is 'Wake-Up Call' for Washington 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 3Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 2Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 3Health News:Insomnia prevalent among cancer patients who receive chemotherapy 2(Date:11/23/2009)...e-FirstCall/--BostonScientificCorporation(NYSE: BS...CareConference,December1-2. ,, RayElliott,Presi...cePresidentandChiefFinancialOfficer,willparticipat...cember1st,beginningatapproximately9:00a.m.E.T. ,...linterestedpartiesatBostonScientific,swebsiteat ww...
(Date:11/23/2009)...swire-FirstCall/--DURECTCorporation(Nasdaq: DRRX )...andJoeStauffer,ChiefMedicalOfficer,willbepresentin...Tuesday,December1at3:30pmEasternTime.Theconference..., (Logo: http://www.newscom.com/cgi-bin/prnh/20...nviatheinternet,pleasegotothedirectconferencelinka...
(Date:11/23/2009)...eportlinker.comannouncesthatanewmarketresearchrepo...DiagnosticImagingMarketto2015 ,, http://www....stic-Imaging-Market-to-2015.html#utm_source=prnews... ,, Description ,, TheFutureoftheDiagn...balMarketsDirect,s"TheFutureoftheDiagnosticImaging...
Breaking Medicine Technology:DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference 2Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 2Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 3Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 4Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 5Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 6Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 7Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 8Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 9Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 10Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 11Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211 a Novel Product Candidate for the Treatment of Respiratory Diseases 50392 1Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211 a Novel Product Candidate for the Treatment of Respiratory Diseases 50392 2Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products 50389 1Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products 50389 2Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products 50389 3Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products 50389 4Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products 50389 5Huge Potential Returns for Healthcare Innovators 50385 1 Other News: